Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

523 results about "Thrombotic disease" patented technology

Thrombotic thrombocytopenic purpura (TTP) is a rare blood disorder characterized by clotting in small blood vessels (thromboses), resulting in a low platelet count.In its full-blown form, the disease consists of the following pentad: Microangiopathic hemolytic anemia. Thrombocytopenic purpura.

Nutritional blend oil with balanced fatty acid component and active component for middle and old aged

The invention relates to a nutritional blend oil with balanced fatty acid components and active components for the middle and old aged, which is prepared by a plurality of plant oils selected from flaxseed oil, walnut oil, double-low rapeseed oil, soybean oil, wheat germ oil, corn oil, teal oil, peanut oil, grape seed oil, rice bran oil, camellia oil, evening primrose seed oil, sunflower seed oil and the like, wherein, Omega 6 serial polyunsaturated fatty acids (PUFA) and Omega 3 serial PUFA are contained to enable the ratio of saturated fatty acid (SFA) to monounsaturated fatty acid (MUFA) to PUFA to be 0.6-0.8:1:1, the ratio of Omega 6 to Omega 3 to be 4:1 in the comprehensive evaluation of the blend oil absorbed by the middle and old aged and the fat from other sources, thereby meeting the recommended value of Chinese Nutrition Society; the nutritional blend oil contains 2% of gama-linolenic acid, thereby beneficial to improving the contents of DH-gama-linolenic acid and arachidonic acid; the total content of lauric acid, myristic acid and palmitic acid contained in the nutritional blend oil is below 8.5% in order to avoid over rising the level of Low density lipoprotein (LDL) in the plasm of the middle and old aged; in addition, the nutritional blend oil also comprises a plurality of active components with oxidation resistant property, so other antioxidants do not need to be added in the blend oil.The blend oil provided by the invention is characterized by low cost, balanced fatty acid nutrition, a plurality of abundant active components and higher security, thereby better improving the health and intelligence of eaters, preventing cardiovascular and cerebrovascular diseases, and avoiding fatness, hyperlipidemia, thrombotic diseases and the like caused by unbalanced fatty nutrition.
Owner:ZHEJIANG OIL MASTER

Ketone compounds and compositions for cholesterol management and related uses

The present invention relates to novel ketone compounds, compositions comprising ketone compounds, and methods useful for treating and preventing cardiovascular diseases, dyslipidemias, dysproteinemias, and glucose metabolism disorders comprising administering a composition comprising a ketone compound. The compounds, compositions, and methods of the invention are also useful for treating and preventing Alzheimer's Disease, Syndrome X, peroxisome proliferator activated receptor-related disorders, septicemia, thrombotic disorders, obesity, pancreatitis, hypertension, renal disease, cancer, inflammation, and impotence. In certain embodiments, the compounds, compositions, and methods of the invention are useful in combination therapy with other therapeutics, such as hypocholesterolemic and hypoglycemic agents.
Owner:ESPERION THERAPEUTICS

Fucosylated glycosaminoglycan derivative and preparation method thereof

InactiveCN102329397APotent anticoagulant activityOrganic active ingredientsBlood disorderOrganosulfateCarboxylic ester
The invention discloses a carboxylic ester of fucosylated glycosaminoglycan (CEFG) with anticoagulation activity, a pharmaceutically acceptable salt thereof, a preparation method of the CEFG and the pharmaceutically acceptable salt thereof, a pharmaceutical composition containing the CEFG or the salt thereof, and application of the pharmaceutical composition in preparation of anticoagulants. The monosaccharides for preparing the CEFG comprise D-glucuronic acid or D-glucuronate (D-GlcU), D-2-deoxy-2-acetyl galactosamine sulfate (D-GalNAcS) and L-fucose sulfate (L-FucS), wherein the molar ratio of D-GlcU to D-GalNAc to L-Fuc to -OSO3<-> is 1:(1+ / -0.3):(1+ / -0.3):(3.5+ / -0.5); the esterification degree of the D-GlcU is not lower than 20%; and the weight average molecular weight of the CEFG is 3000-20000 Da. The glycosylated chondroitin sulfate esterification derivative has strong anticoagulation activity, and can be applied in preparation of drugs for preventing and / or treating thrombotic diseases.
Owner:KUNMING INST OF BOTANY - CHINESE ACAD OF SCI

Therapeutic use of soluble CD39L3

ActiveUS7247300B1Enhance ADPase activityDiminish unwanted related activityHydrolasesPeptide/protein ingredientsDiseasePlatelet inhibition
The present invention provides soluble forms of CD39L3 polypeptides and compositions, and methods useful inhibiting platelet activation and recruitment for the treatment and prevention of thrombotic disorders in mammals administered with soluble forms of CD39L3 polypeptides.
Owner:ASTRAZENECA AB

Shear controlled release for stenotic lesions and thrombolytic therapies

The invention provides compositions and methods for treating or imaging stenosis, stenotic lesions, occluded lumens, embolic phenomena or thrombotic disorders. The invention further provides compositions and methods for treating internal hemorrhage.
Owner:PRESIDENT & FELLOWS OF HARVARD COLLEGE

Fuc3S4S substituted oligo-glycosaminoglycan and preparation method thereof

The invention discloses a Fuc3S4S substituted oligo-glycosaminoglycan with the weight-average molecular weight of about 4.5-9kD, a medicine composition containing the Fuc3S4S substituted oligo-glycosaminoglycan, preparation methods thereof and an application thereof in preparing medicines for preventing or treating thrombotic diseases. The oligo-glycosaminoglycan has a structure shown as the formula (I); in the formula (I), a substituent group is defined as the specification. The Fuc3S4S substituted oligo-glycosaminoglycan and the medicine composition thereof have strong-effect factor X enzyme inhibition activity and HC-II depended antithrombase activity, and can be used for preparing antithrombus medicines.
Owner:JIUZHITANG +2

Dipeptide analogs as coagulation factor inhibitors

Disclosed are novel dipeptide analogs compounds of Formula (I), (II) or (III):or a stereoisomer, a tautomer, a pharmaceutically acceptable salt, a solvate, or a prodrug thereof, which are inhibitors of factor XIa and / or plasma kallikrein, compositions containing them, and methods of using them, for example, for the treatment or prophylaxis of thrombotic diseases.
Owner:BRISTOL MYERS SQUIBB CO
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products